Clinical Research Directory

Inclusion Criteria * Targeted therapy is acceptable within 1-2 months after liver transplantation. * Immunosuppressive regimen consists of calcineurin inhibitor, mycophenolate mofetil and sirolimus. * All male and female participants must take reliable contraceptive measures during the trial and within four weeks after the end of the trial. * The definition of high-risk patients: * The PET scan is positive before LDLT; * Tumors beyond USCF criteria * Poorly-differentiated tumor; * The patients who has poor AFP response (\<15%)or AFP\>400 ng/ml after LRT after conventional LRT (RFA、PEI or TACE) Exclusion Criteria * Life expectancy is less than 3 months * Patients are with other malignant tumors simultaneously. * Patients are anaphylaxis to the inactive ingredients of lenvatinib or drugs. * Pregnant or lactating women (Female participants need pregnancy test within 7 days before treatment). * Preoperative history of severe cardiovascular disease: congestive heart failure \> NYHA grade 2; active coronary heart disease (myocardial infarction occurred within 6 months before entry into the study); severe arrhythmia requiring antiarrhythmic treatment (allowable use of beta-blockers or digoxin); uncontrolled hypertension. * History of HIV infection. * Severe clinical active infections (\> NCI-CTCAE version 3.0). * Epilepsy patients requires medication (e.g. steroids or antiepileptic drugs). * Patients with kidney diseases requires renal dialysis. * Drug abuse, medical symptoms, mental illness or social status that may interfere with participants' participation in research or evaluation of research results. * Patients who could not swallow oral drugs, such as those with severe upper gastrointestinal obstruction and need gastric tube feeding.